Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01190839 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
A Phase 3 study, sponsored by Janssen Biotech.
- Terminated
- Registry status
- Phase 3
- Development phase
- 297
- Enrollment target
NCT01190839 is a Phase 3 study that was terminated before completion, run by Janssen Biotech. The registered enrollment target is 297 participants.
The verdict
NCT01190839, a Phase 3 study, was terminated before completion, sponsored by Janssen Biotech.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 297 participants
- Enrollment target
Study Summary
REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection. This study will compare the effects (both good and bad) of REMICADE (infliximab) to those of placebo. Placebo looks like the drug being studied but has no active ingredients.
Interventions
- DRUG Placebo
- BIOLOGICAL Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01190839
The ClinicalTrials.gov registry entry for NCT01190839 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Biotech, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01190839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01190839 about?
NCT01190839 is a clinical study titled "A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence". REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection. This study will compare the effects (both good and bad) of REMICADE (infliximab) to those of placebo...
What is the current status of trial NCT01190839?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 297 participants. The study started on 2010-11. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01190839?
The interventions under investigation include: Placebo (DRUG), Infliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01190839?
This trial is sponsored by Janssen Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.